1. Thomas B. Bersot. Drug therapy for hypercholesterolemia and dyslipidemia. Goodman & Gilman’s: The pharmacological basics of Therapeutics. 12th Edition. New York Mc Graw Hill Medical 2011. Page – 901-903.
2. Shashank R Joshi. Saroglitazar for the treatment of dyslipidemia in diabetic patients. NIH National library of Medicine, National Center for Biotechnology Information. Pubmed.gov. March 2015. [Accessed 27th October 2020] https://pubmed.ncbi.nlm.nih.gov/25674933/#:~:text=The%20results%20of%20Phase%20III,dyslipidemia%20and%20associated%20cardiovascular%20risk.
3. Upendra kaul, Peeyush jain, Ranjan kachru, Vineet bhatia, Priyadarshini arambam, Sudhir shekhawat, Yumnam diana, Kavita rawat, Shilpi singh and Ashok jaiswal. A Prospective, Multicentric Study to Evaluate the Effects of Saroglitazar on Non-HDL Cholesterol and Small Dense LDL Particles in Patients with Diabetic Dyslipidemia. American diabetic association. July 2018. [Accessed 27th October 2020] https://diabetes.diabetesjournals.org/content/67/Supplement_1/38-LB
4. Cadila Healthcare Limited. August 2013. [Accessed 27th October 2020] http://www.lipaglyn.com/downloads/saroglitazar/Lipaglyn_PI_Booklet.pdf